Identifying inflammatory phenotypes to target mechanism-specific treatments in sepsis

Hernando Gómez; Renee R Anderko; Joseph A Carcillo

doi:10.1016/j.xcrm.2022.100823

Identifying inflammatory phenotypes to target mechanism-specific treatments in sepsis

Cell Rep Med. 2022 Nov 15;3(11):100823. doi: 10.1016/j.xcrm.2022.100823.

Authors

Hernando Gómez¹, Renee R Anderko², Joseph A Carcillo³

Affiliations

¹ Program for Critical Care Nephrology, Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA. Electronic address: gomezh@upmc.edu.
² Department of Surgery, Division of Surgical Oncology, University of Pittsburgh, Pittsburgh, PA, USA.
³ Program for Critical Care Nephrology, Department of Critical Care Medicine, University of Pittsburgh, Pittsburgh, PA, USA.

Abstract

A clinical trial by Leventogiannis et al.¹ suggests that ferritin and HLA-DR monocyte receptor expression can identify septic patients with macrophage-activation-like syndrome (MALS), or immunoparalysis, and that targeting IL-1ra treatment with this strategy may improve outcomes.

Publication types

Comment

MeSH terms

Clinical Trials as Topic
HLA-DR Antigens / genetics
Humans
Macrophage Activation Syndrome*
Monocytes
Phenotype
Sepsis* / diagnosis

Substances

HLA-DR Antigens